A 35-year-old man with moderate persistent asthma is on inhaled beclomethasone 250 µg twice daily and albuterol as needed. He reports using the rescue inhaler 4–5 times per week despite adherence to the ICS. His FEV₁ is 72% of predicted. What is the most appropriate next step in management?

## Stepwise Management of Inadequately Controlled Asthma on ICS Monotherapy ### Clinical Assessment **Current Status:** - Patient is on **Step 3** asthma therapy (ICS monotherapy at moderate dose) - **Inadequate control** indicators: - Rescue inhaler use 4–5 times per week (goal: ≤2 days/week) - FEV₁ 72% of predicted (goal: ≥80%) - Symptoms suggest need for Step 4 therapy ### GINA/NAEPP Stepwise Approach ```mermaid flowchart TD A[Asthma control assessment]:::outcome --> B{Controlled?}:::decision B -->|Yes| C[Continue current step]:::action B -->|No| D{On ICS monotherapy?}:::decision D -->|Yes| E[Add LABA to ICS]:::action D -->|No| F[Increase ICS dose or add LABA]:::action E --> G[Reassess in 2-4 weeks]:::action F --> G G --> H{Controlled?}:::decision H -->|Yes| I[Maintain ICS/LABA]:::outcome H -->|No| J[Consider biologic or add 3rd agent]:::action ``` **Key Point:** The stepwise approach mandates adding a second controller agent (LABA) before increasing ICS dose alone, because ICS/LABA combination is more effective than high-dose ICS monotherapy. **High-Yield:** **ICS/LABA combinations are superior to high-dose ICS monotherapy** for moderate-to-severe asthma. This is the cornerstone of modern asthma management. ### Why ICS + LABA Is the Next Step | Feature | ICS Monotherapy | ICS + LABA | |---|---|---| | Rescue use | 4–5 times/week | Typically ≤2 days/week | | FEV₁ improvement | Modest (5–10%) | Greater (10–15%) | | Exacerbation reduction | Moderate | Significant | | Guideline recommendation | Step 3 | Step 4 (inadequate control on Step 3) | **Clinical Pearl:** LABA must ALWAYS be combined with ICS in asthma (never monotherapy) because LABAs increase mortality when used alone. ICS/LABA fixed-dose combinations (e.g., fluticasone/salmeterol, budesonide/formoterol) improve adherence and ensure concurrent ICS use. **Mnemonic:** **LABA Rule** — **L**ABA **A**lways with **B**uddy (ICS), **A**lways avoid alone. ### Why Other Options Are Incorrect 1. **Increasing ICS monotherapy to 500 µg twice daily:** This violates stepwise management. High-dose ICS monotherapy is less effective than standard-dose ICS/LABA for this patient's level of control loss. It also increases systemic absorption and adverse effects without the synergistic benefit of LABA. 2. **Montelukast monotherapy:** Leukotriene receptor antagonists are weaker than ICS and should not replace ICS. They may be added as a third agent in severe asthma, but never as a substitute for ICS. 3. **Immediate biologic therapy (omalizumab):** Biologics are reserved for severe, difficult-to-control asthma or specific phenotypes (allergic asthma for omalizumab, eosinophilic for mepolizumab, etc.). This patient has not yet failed ICS/LABA therapy, so biologic therapy is premature. [cite:GINA 2023; Harrison 21e Ch 297]